Tag Archives: MAP
MAP to Breast Cancer Prevention for Postmenopausal Women
The biggest breast cancer prevention study of 2011 provides a risk reduction MAP for women at moderate risk for developing the disease. Specifically, the MAP3 (MAmmary Prevention) trial tested whether the drug exemestane, in the class called aromatase inhibitors (AIs for short), could decrease breast cancer risk among postmenopausal women. This randomized controlled clinical trial [...]
